

## Disclosures

### Personal Commercial (14)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Abbott Laboratories	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Astra Zeneca	Research/Research Grants	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Berlin Heart	Data Safety Monitoring Board	Modest (< \$5,000)	<a href="#">Cardiothoracic Surgery Heart Failure and Cardiomyopathies</a>
Bivacor	Data Safety Monitoring Board	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
BrioHealth Solutions	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
CorWave	Consultant Fees/Honoraria	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Endotronix	Consultant Fees/Honoraria	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Medtronic	Research/Research Grants ‡ DT-PAS and Apogee	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Nuwellis	Research/Research Grants	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
PHOPE	Consultant Fees/Honoraria	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Procyron	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Procyron	Stock	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
TenNor Therapeutics	Consultant Fees/Honoraria	None (\$0)	<a href="#">Other</a>

### Additional Personal Commercial Disclosures for Education Activities (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott	Research/Research Grants ‡ TEAM HF	Modest (< \$5,000)	
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
BrioHealth Solutions, maker of BrioVAD	Research/Research Grants ‡ INNOVATE	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Zoll	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
JACC- HF: editorial board consultant	Other	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
OPTN Heart Committee	Other - Member of Heart Committee	None (\$0)	<a href="#">Other</a>
STS-Intermacs- leadership committee	Other	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (2)

Funding Source	Institutional Compensation Level
Grand Rounds, Multiple Centers (Mount Sinai, Univ of Minnesota, Yale, North Shore, Scripps, MCOW, Univ Hospitals of Cleveland, UVA, Utah, UCSF)	Modest (< \$5,000)

Funding Source	Institutional Compensation Level
none	None (\$0)

Expert Witness Testimony (6)

Year	Case Title	Represented	Description	Compensation
Self				
2025	Tacrolimus dosing in heart Transplant	Defendant	Nursing home incorrectly dosed tacrolimus	Significant (>= \$5,000)
2024	Cardiogenic shock	Third Party	Pt arrived in shock and diagnosis missed. I represented hospital, not a physician	Significant (>= \$5,000)
2021	Endocarditis	Plaintiff	Pt had endocarditis. I was consultant. Did not go to trial.	Modest (< \$5,000)
2020	plaintiff vs CVS	Third Party	Pt stopped Brilinta after PCI with acute stent thrombosis and shock I was consultant regarding transplant or VAD need	Modest (< \$5,000)
2017	Endocarditis	Plaintiff † none	Patient developed endocarditis and needed an AVR. ER did not respond to positive blood cultures obtained.	Significant (>= \$5,000)
2013	PEripartum cardiomyopathy, cardiogenic shock	Defendant † none	I provided knowlege of the course of peripartum cardiomyopathy. I provided information on mortality for peripartum cardiomyopathy, shock etc.	None (\$0)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/20/2025  
URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/20/2025  
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/20/2025  
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/20/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.